# A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

> **NCT05317078** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 3 (actual)

## Conditions studied

- Non-squamous Non-small Cell Lung Cancer
- Epithelial Ovarian Cancer
- Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors

## Interventions

- **DRUG:** AMG 794

## Key facts

- **NCT ID:** NCT05317078
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-28
- **Primary completion:** 2023-12-19
- **Final completion:** 2024-04-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Sponsor strategic decision
- **Last updated:** 2025-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05317078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05317078, "A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05317078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*